SCHEMBL7466728

SCHEMBL7466728

Fc1ccc(-c2ncc(Br)cn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.48
RAB9A P51151 6/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NFKB1 P19838 2/20 0.48
NFKB2 Q00653 2/20 0.48
RELA Q04206 2/20 0.48
AHR P35869 2/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ATM Q13315 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HDAC4 P56524 3/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16222829 0.83 NPC1 (0.65) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL19463204 0.77 RAB9A (0.56) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2741556 0.77 ACHE (0.46) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL1227061 0.77 NPC1 (0.56) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL22130293 0.77 RAB9A (0.68) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL1772821 0.77 RAB9A (0.48) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL4480260 0.77 TRPV1 (0.50) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL1877775 0.76 NPC1 (0.69) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2741565 0.76 ACHE (0.44) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL12056680 0.76 NPC1 (0.43) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034105-A1 Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) 2026-02-05 US disclosed
EP-0817773-B1 PYRIMIDINE COMPOUNDS QINETIQ LTD (GB) 2002-06-12 EP disclosed
US-6121448-A LIQUID CRYSTALLINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITTANIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 2000-09-19 US disclosed
US-5986096-A REACTION OF HYDROGEN IODIDE WITH CHLORO-5-BROMOPYRIMIDINE THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S A GOVERNMENT OF THE U.K. OF GT. BRITAIN & N. IRELAND OF DEFENCE EVALUATION & RESEARCH AGENCY (GB) 1999-11-16 US disclosed
WO-1996030344-A9 PYRIMIDINE COMPOUNDS 1999-02-11 WO disclosed
EP-0817773-A2 PYRIMIDINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE (GB) 1998-01-14 EP disclosed
WO-1996030344-A2 PYRIMIDINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE (GB) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034105-A1 Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors PIK3R1, PIK3R4, PIK3R2 NPC1 134/4885RAB9A 1508/4885SMN1; SMN2 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.